News

The regulator approved the new drug application (NDA) for PF708, which was submitted under the 505(b)(2) regulatory pathway with Eli Lilly and Company’s Forteo as the reference medicine.

The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial, which achieved their primary objective of usability and pharmacokinetic (PK)

Johnson & Johnson (J&J) will use the investment to advance research and development and delivery programmes to eliminate both diseases by 2030. The company will appoint a team

Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous

The company was founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine (Cell

Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide. However, the agreement grants Takeda the option, prior to

Descovy for PrEP has been approved to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing minimum 35kg who are HIV-negative and at-risk for

Proceeds from the financing will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all

This new indication was granted full approval based on the overall survival (OS) findings from the Phase 3 KEYNOTE-042 trial, including data from an extension of the global